Cardioprotective effects and the mechanisms of terminal warm blood cardioplegia in pediatric cardiac surgery  by Toyoda, Yoshiya et al.
Cardioprotective effects and the mechanisms of terminal
warm blood cardioplegia in pediatric cardiac surgery
Yoshiya Toyoda, MDa,b
Masahiro Yamaguchi, MDa
Naoki Yoshimura, MDa
Shigeteru Oka, MDa
Yutaka Okita, MDb
Objectives: Terminal warm blood cardioplegia has been shown to enhance myo-
cardial protection in adult patients. However, the cardioprotective effects and the
mechanisms of terminal warm blood cardioplegia in pediatric heart surgery were
still unknown.
Methods: One hundred three consecutive patients were prospectively randomized to
one of two groups. In the control group (n  52), myocardial protection was
achieved with intermittent hyperkalemic cold blood cardioplegia and topical cardiac
cooling. In the terminal warm blood cardioplegia group (n  51), this was supple-
mented with terminal warm blood cardioplegia before the aorta was declamped.
Arterial and coronary sinus blood samples were analyzed to determine myocardial
energy metabolism and tissue injury.
Results: There were no significant differences between the two groups in age (5.5
 0.6 years in the control group vs 5.6  0.5 years in the terminal warm blood
cardioplegia group), body weight (17.2  1.4 kg in the control group vs 19.8  1.7
kg in the terminal warm blood cardioplegia group), percentage of cyanotic heart
diseases (50% in the control group vs 51% in the terminal warm blood cardioplegia
group), number of patients who required right ventriculotomy (33% in the control
group vs 39% in the terminal warm blood cardioplegia group), cardiopulmonary
bypass time (194  12.1 minutes in the control group vs 177  8.6 minutes in the
terminal warm blood cardioplegia group), aortic crossclamp time (83.3  5.9
minutes in the control group vs 82.3  5 minutes in the terminal warm blood
cardioplegia group), lowest rectal temperature (27.4 0.3°C in the control group vs
28.1  0.3°C in the terminal warm blood cardioplegia group), and myocardial
temperature (9.6  0.6°C in the control group vs 9.6  0.7°C in the terminal warm
blood cardioplegia group). Spontaneous defibrillation occurred after reperfusion in
80% in the terminal warm blood cardioplegia group, which was significantly (P 
.05) higher than the control group (62%). The lactate extraction rate at 60 minutes
of reperfusion was significantly (P  .05) higher in the terminal warm blood
cardioplegia group (9.0  2.8%) than the control group (3.3  2.4%). The
postreperfusion values of cardiac troponin T (7.4 0.6 ng/mL vs 11.2 1.0 ng/mL
at 6 hours; 4.6  0.6 ng/mL vs 9.3  1.6 ng/mL at 18 hours) and heart-type fatty
acid binding protein (137  28 ng/mL vs 240  30 ng/mL at 2 hours; 88  19
ng/mL vs 162  26 ng/mL at 3 hours) were significantly (P  .05 vs the control
group) lower in the terminal warm blood cardioplegia group.
Conclusion: Terminal warm blood cardioplegia enhances myocardial protection in
pediatric cardiac surgery by an improvement in aerobic energy metabolism and a
reduction of myocardial injury or necrosis.
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Hypothermia continues to be the standardmethod for myocardial protection in heartsurgery since the 1950s.1-3 Previously, wealso have shown that hypothermia is im-portant for myocardial protection in pedi-atric heart surgery, especially in cyanotic
heart diseases in which the noncoronary collateral vessel
flow may contribute to myocardial rewarming and in that
way increase ischemic injury.4 Although hypothermia re-
duces oxygen demands, thereby prolonging tolerable isch-
emic arrest time, hypothermia is also reported to be associ-
ated with detrimental effects on enzymatic and metabolic
function.5
Recent evidence obtained in adult patients demonstrated
that warm heart surgery might provide better protection for
surgical ischemia/reperfusion injury.5 Teoh and associates6
demonstrated in a prospective, randomized trial in patients
undergoing elective coronary artery bypass that terminal
warm blood cardioplegia (TWBCP) enhanced myocardial
protection afforded by intermittent cold blood cardioplegia.
TWBCP is now often used in adult heart surgery but is
rarely used in pediatric heart surgery.7 Because develop-
mental differences exist in myocardial metabolism and re-
sponse to ischemia/reperfusion,1 the effects of TWBCP in
pediatric heart surgery need to be elucidated. The purpose of
this study was to determine the cardioprotective effects and
the mechanisms of TWBCP in pediatric heart surgery.
Methods
Patient Population
One hundred three consecutive patients undergoing heart surgery
for congenital heart diseases at Kobe Children’s Hospital between
July 1997 and September 1998 were prospectively randomized to
one of two groups. The control group (C, n  52) received cold
blood cardioplegia for myocardial protection. The terminal warm
blood cardioplegia group (T, n  51) received cold blood cardio-
plegia with terminal warm blood cardioplegia. The patients’ ages
were 5.6  0.4 years ranging from 0 to 18 years, and the body
weight was 18.4  1.1 kg. The two groups were similar with
respect to disease, and about half of the patients in both groups had
cyanosis. Preoperative patient characteristics are summarized in
Table 1.
Operative Procedure
Anesthesia was induced and maintained with fentanyl (50 to 100
g/kg) and vecuronium. Patients were ventilated with oxygen, air,
and isoflurane, and ventilation was adjusted to maintain normo-
carbia. Cardiopulmonary bypass was instituted with an ascending
aortic cannula, bicaval venous cannulas, and a systemic ventricular
vent. Systemic flow was maintained between 2.2 and 2.6 L/minute/
m2, and mean arterial pressure between 40 and 60 mm Hg. Mod-
erate systemic hypothermia was used with a lowest rectal temper-
ature of 27.7  0.2°C. We have used pH stat strategy for pH
management by the addition of carbon dioxide as appropriate.
Protocol of Myocardial Protection
Myocardial protection was achieved with intermittent cold blood
cardioplegia with topical heart cooling in all patients. Cardioplegic
solution of 300 mL/m2 of body surface area was initially infused
into the aortic root at 30 mm Hg to achieve cardiac arrest, with
subsequent doses of 150 mL/m2 of body surface area every 20
minutes. Blood cardioplegia was made by mixing a hyperkalemic
crystalloid solution8 with oxygenated blood in a 1:2 dilution and
cooled to 9°C. At the start of reperfusion, the aorta was partially
declamped for 3 minutes, and the aortic root pressure was kept less
than 30 mm Hg to reduce reperfusion injury; then the aorta was
fully declamped. In group T, an additional 300 mL/m2 of body
surface area of warm (35°C) blood cardioplegia was infused into
the aortic root at a pressure of 30 mm Hg just before declamping
the aorta. The composition of terminal warm blood cardioplegia
was the same as the cold blood cardioplegia, other than tempera-
ture, and is shown in Table 2.
Electrical defibrillation was applied to the heart if ventricular
fibrillation persisted beyond 3 minutes after declamping the aorta.
We avoided inotropic support as much as possible before coming
off from cardiopulmonary bypass, but if systolic blood pressure
was less than 50 to 70 mm Hg, depending on the patient’s age,
with left atrial pressure between 10 and 12 mm Hg, inotropic
support was initiated even during cardiopulmonary bypass. After
weaning from cardiopulmonary bypass, if systolic blood pressure
was lower than 60 to 80 mm Hg or urine output was less than 1
mL/kg/hour, we started inotropic support after optimizing rhythm,
afterload, and preload with left atrial pressure between 10 and 12
mm Hg.
TABLE 1. Patient characteristics
Control
(n  52)
TWBCP
(n  51) P value
Age (years)
mean 5.5 0.6 5.6 0.5 .867
range 0-13 0-18
Body weight (kg) 17.2 1.4 19.8 1.7 .243
Sex, (M/F) 27/25 33/18 .232
Pathology, (n)
Acyanotic 26 25
VSD, ASD 20 22
Aortic or mitral valve 4 2
Others 2 1
Cyanotic 26 26
TF with PS or PA 11 15
TGA 5 1
TAPVR 0 2
SV 5 4
Others 5 4
Data are shown as the mean  standard error of the mean for age and
body weight, or the actual number for the rest of the parameters.
VSD, Ventricular septal defect; ASD, atrial septal defect; TF, tetralogy of
Fallot; PS, pulmonary artery stenosis; PA, pulmonary atresia; TGA, trans-
position of great arteries; TAPVR, total anomalous pulmonary venous
return; SV, single ventricle.
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Measurements
Myocardial temperature was measured at the ventricular septum
near the cardiac apex just before release of the aortic crossclamp
using a needle thermistor. Hemodynamic measurements included
heart rate, blood pressure, and left atrial pressure. Arterial and
coronary sinus blood samples were taken at 0, 10, 20, 30, 45, and
60 minutes after the aortic crossclamp release and analyzed for
blood gas and lactate. Oxygen content was calculated from the
hemoglobin (Hb), the SO2, and the PO2 according to the equation:
O2 content 1.34 Hb  SO2  0.0031 PO2
Myocardial oxygen extraction and myocardial lactate extraction
were calculated as the difference between the arterial and coronary
sinus content. Lactate extraction rate was calculated by the equa-
tion:
Lactate extraction rate (La  Lcs) 100/La
As a marker of myocardial injury, serum concentration of
cardiac troponin T and heart-type fatty acid binding protein (h-
FABP) were measured. Cardiac troponin T was measured at 0, 1,
3, 6, and 18 hours after the aortic crossclamp release, and h-FABP
at 0, 1, 2, and 3 hours. Cardiac troponin T was measured with an
enzyme immunoassay and h-FABP with a sandwich enzyme im-
munoassay with two different anti-h-FABP monoclonal antibod-
ies.9
Assessment of Clinical Outcome
Intraoperative and postoperative clinical parameters were used to
assess clinical outcome. Intraoperative parameters included heart-
beat recovery after release of the aortic crossclamp, either spon-
taneously or with electrical defibrillation, and intraoperative re-
quirement of pacing and inotropes for weaning patients from
cardiopulmonary bypass. Postoperative parameters included dura-
tion and maximum doses of inotropic support, duration of venti-
latory support, intensive care unit stay, and mortality rate. Dopa-
mine was the catecholamine of the first choice and dobutamine
was the second. When dopamine and dobutamine failed to provide
sufficient inotropic support, epinephrine was used.
Statistics
Data were collected prospectively and analyzed for all 103 patients
recruited. Statistical analysis was performed using SAS version
6.12 software package (SAS Institute, Cary, NC). The mean  the
standard error of the mean for all data was calculated for all
variables. Intragroup analysis was performed by a two-tailed
paired t test or repeated measures analysis of variance with Bon-
ferroni posthoc test as appropriate. Intergroup analysis was per-
formed by a two-tailed unpaired t test or repeated measures anal-
ysis of variance with Bonferroni post-hoc test as appropriate. A
Fisher’s exact test was used for categorical variables.
Results
Clinical Outcome
Intraoperative data are shown in Table 3. Right ventriculot-
omy was required for repair in 33% of group C and 39% of
the group T (P  .314). No significant differences were
observed between the groups as far as the cardiopulmonary
bypass time, the aortic crossclamp time, and the lowest
rectal temperature during cardiopulmonary bypass. Myocar-
dial temperature just before release of the aortic crossclamp
was 9.6  0.6°C in group C and the temperature just before
the start of TWBCP infusion was 9.6 0.7°C (NS vs group
T). In group T, infusion of TWBCP significantly increased
myocardial temperature from 9.6  0.7°C to 20.0  0.7°C
(P .001). Spontaneous defibrillation occurred within min-
utes after release of the aortic crossclamp in 80% of the
patients receiving TWBCP, which was significantly (P 
.029) greater than the control. Ventricular pacing was re-
quired for weaning patients from cardiopulmonary bypass
in 25% of group C and 16% of group T (P  .177), and
inotropes were required for 15% in group C whereas no
patients required inotropes in group T (P  .003). In the
intensive care unit, however, inotropic support was required
for 47 of 52 patients (90.4%) in group C and 49 of 51
patients (96.1%) in group T (P  .437).
Postoperative data are shown in Table 4. All clinical
outcome parameters including systemic ventricular ejection
TABLE 2. Composition of TWBCP
Na (mmol/L) 97.7 1.2
K (mmol/L) 18.7 0.3
Cl (mmol/L) 90.4 0.8
Mg2 (mmol/L) 1.0 0.01
Ca2 (mmol/L) 0.73 0.01
pH 7.51 0.01
HCO3 (mmol/L) 17.4 0.3
Hematocrit (%) 18.6 0.6
Osmolarity (mOsm/L) 339 3.1
All data are shown as the mean  standard error of the mean for each
composition.
TABLE 3. Summary of intraoperative data
Control
(n  52)
TWBCP
(n  51) P value
Required Right
Ventriculotomy (%)
33 39 .314
CPB time (minutes) 194 12.1 177 8.6 .281
AoX time (minutes) 83.3 5.9 82.3 5.0 .905
Lowest rectal temperature
during CPB (°C)
27.4 0.3 28.1 0.3 .076
Myocardial temperature (°C) 9.6 0.6 9.6 0.7 .997
Spontaneous beat after
declamping (%)
62 80 .029
Pacing at weaning from
CPB (%)
25 16 .177
Inotropes at weaning from
CPB (%)
15 0 .003
Data are shown as the mean  standard error of the mean or the
percentage for each group. Myocardial temperature in the group T was the
temperature just prior to the start of TWBCP infusion. CPB, Cardiopulmo-
nary bypass; AoX, aortic crossclamp.
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fraction, duration and maximum doses of inotropic support,
ventilatory support, intensive care unit stay, and mortality
rate were better for patients receiving TWBCP compared
with the control group, although no statistical significance
was observed between the groups.
Myocardial Oxygen and Lactate Extraction
No significant difference in myocardial oxygen extraction
was observed between the groups throughout the initial 60
minutes of reperfusion (Figure 1). However, myocardial
lactate extraction rate was increased at all time points in
group T compared with group C (Figure 2). The lactate
extraction rate at 60 minutes of reperfusion was signifi-
cantly (P  .004) higher in group T (9.0  2.8%) than
group C (3.3  2.4%).
Cardiac Troponin T and Heart-type Fatty Acid
Binding Protein
Serum concentrations of cardiac troponin T were 7.4  0.6
ng/mL at 6 hours and 4.6  0.6 ng/mL at 18 hours in the
TWBCP group, which were significantly (P  .05) lower
than 11.2  1.0 ng/mL and 9.3  1.6 ng/mL in the control
group, respectively (Figure 3). No significant differences in
serum concentration of h-FABP were observed between the
groups immediately and 1 hour after the aortic crossclamp
release. However, h-FABP was 137  28 ng/mL and 88 
19 ng/mL at 2 and 3 hours, respectively, in group T, which
were significantly (P  .05) lower than 240  30 ng/mL
and 162  26 ng/mL at the same time points, respectively,
in group C (Figure 4).
Effects of TWBCP in Younger Patients (Age < 2
Years)
We compared 13 patients in group C and 9 patients in group
T whose ages were equal to or less than 2 years. Patient
characteristics are shown in the Table 5. Myocardial lactate
extraction rate was increased at all time points up to 30
minutes of reperfusion in group T compared with group C
(Figure 5). The lactate extraction rate was 6.4  1.5% at 30
minutes of reperfusion in group T, which was significantly
(P  .03) higher than 8.4  3.7% in group C. Cardiac
troponin T was decreased in group T compared with group
C at any time point; however, no statistical significance was
observed between the groups because of the small number
(Figure 6).
Effects of TWBCP in Patients with Cyanosis
There were 26 patients with cyanosis in each group. Patient
characteristics are shown in Table 6. Significantly fewer
patients required inotropes for weaning from cardiopulmo-
TABLE 4. Summary of postoperative data
Control
(n  52)
TWBCP
(n  51) P value
Inotropic support duration
(hours)
94.9 10.5 88.2 9.7 .641
Maximum doses of
Inotrope (g/kg/min)
Dopamine 8.4 0.6 7.7 0.4 .320
Dobutamine 3.2 0.5 1.8 0.5 .075
Epinephrine 0.023 0.008 0.015 0.005 .421
Ventilatory support
duration (hours)
67.8 12.8 61.8 9.5 .706
ICU stay (days) 7.1 0.9 5.8 0.6 .263
Mortality (%) 7.7 2.0 .187
Data are shown as the mean  standard error of the mean or the
percentage for mortality rate. ICU, Intensive care unit. Figure 1. Oxygen extraction during initial 60 minutes of reperfu-
sion after aortic crossclamp release. All results are shown as
mean  standard error of mean for each group.
Figure 2. Lactate extraction rate during initial 60 minutes of
reperfusion after aortic crossclamp release. All results are
shown as mean  standard error of mean for each group. Sig-
nificant differences: *P < .05 vs control.
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nary bypass in group T compared with group C. The myo-
cardial lactate extraction rate was similar up to 45 minutes
of reperfusion between the groups (Figure 7). The lactate
extraction rate was 7.6  2.7% at 60 minutes of reperfusion
in group T, which was significantly (P  .037) higher than
3.0  3.4% in group C. No significant differences in
cardiac troponin T were observed between the groups at any
time (Figure 8).
Discussion
In this article, we show the cardioprotective effects and the
mechanisms of terminal warm blood cardioplegia in pedi-
atric heart surgery. Our data demonstrated that, with
TWBCP, a significantly higher number of hearts resumed
normal sinus rhythm spontaneously and all hearts could be
weaned from cardiopulmonary bypass with no inotropic
support, indicating that TWBCP enhances myocardial pro-
tection achieved with cold blood cardioplegia. Our results
also show that TWBCP significantly increased lactate ex-
traction rate and significantly decreased serum concentra-
tion of cardiac troponin T and h-FABP, indicating that the
mechanisms by which TWBCP affords cardioprotection
include improvement in aerobic energy metabolism and
reduction of myocardial injury or necrosis.
Figure 3. Serum concentration of cardiac troponin T 0, 1, 3, 6, and
18 hours after aortic crossclamp release. All results are shown as
mean  standard error of mean for each group. Significant
differences: *P < .05 vs control.
Figure 4. Serum concentration of heart-type fatty acid binding
protein (FABP) 0, 1, 2, and 3 hours after the aortic crossclamp
release. All results are shown as mean  standard error of mean
for each group. Significant differences: *P < .05 vs control.
TABLE 5. Patient characteristics (age < 2 years)
Control
(n  13)
TWBCP
(n  9) P value
Age (months) 10.8 2.5 15.3 2.6 .241
Body weight (kg) 6.2 0.6 8.2 0.7 .042
Cyanotic (%) 46 22 .246
CPB time (minutes) 185 32 168 14 .676
AoX time (minutes) 79.1 11.2 84.4 10.3 .747
Lowest rectal temperature
during CPB (°C)
26.9 0.4 27.3 0.5 .509
Myocardial temperature (°C) 11.7 1.9 9.3 1.6 .368
Spontaneous beat after
declamping (%)
69 89 .293
Inotropes at weaning from
CPB (%)
31 0 .098
Inotropic support duration
(hours)
103 16 98 16 .835
Ventilatory support duration
(hours)
111 24 91 19 .553
ICU stay (days) 8.8 1.7 7.3 1.0 .499
Mortality (%) 14 0 .338
Data are shown as the mean  standard error of the mean or the
percentage of the patients in each group. Myocardial temperature in the
group T was the temperature just prior to the start of TWBCP infusion.
CPB, Cardiopulmonary bypass; AoX, aortic crossclamp; ICU, intensive care
unit.
Figure 5. Effects of TWBCP in younger patients (age < 2 years).
Lactate extraction rate during initial 30 minutes of reperfusion
after aortic crossclamp release. All results are shown as mean
standard error of mean for each group. Significant differences:
*P < .05 vs control.
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We have used cardiac troponin T and h-FABP as a
marker of myocardial injury because recent reports have
suggested that both troponin T and h-FABP are more sen-
sitive and specific to myocardial injury compared with
creatine kinase-MB isoenzyme.9,10 Troponin T is one of
three components of troponin that is a major accessory
protein associated with actin filaments and mediates Ca2
regulation of muscle contraction.11 Because most cardiac
troponin T is myofibril bound, its release in serum is ex-
pected to correlate with the extent of myocardial necrosis.
Furthermore, its release beyond several hours is reported to
derive from myofibril-bound troponin T that is compart-
mented in the cell, but not from cytosolic troponin T that is
released earlier after ischemic events.12 Our data showed
that serum concentration of troponin T was significantly
decreased with TWBCP at 6 and 18 hours after reperfusion
compared with the control, indicating TWBCP significantly
reduced myocardial necrosis resulting in decreased release
of myofibril-bound troponin T into the serum.
Human h-FABP is a cytoplasmic protein abundant in the
myocardial cells, has a lower molecular weight (14.9 kDa)
compared with creatine kinase-MB isoenzyme (80 kDa) and
troponin T (32 kDa), and is the key fatty acid carrier protein
in the cytosol.13 H-FABP is released from cells into the
circulation shortly after the onset of cell injury because of
Figure 6. Effects of TWBCP in younger patients (age < 2 years).
Serum concentration of cardiac troponin T 0, 1, 3, 6, and 18 hours
after aortic crossclamp release. All results are shown as mean
standard error of mean for each group.
TABLE 6. Patient characteristics (cyanotic group)
Control
(n  26)
TWBCP
(n  26) P value
Age (years) 6.2 0.8 5.3 0.4 .293
Body weight (kg) 17.1 1.7 16.9 0.8 .909
CPB time (minutes) 250 17 214 10 .072
AoX time (minutes) 97.2 10.3 88.6 6.8 .488
Lowest rectal temperature
during CPB (°C)
26.1 0.2 26.7 0.2 .082
Myocardial temperature (°C) 9.5 0.9 8.2 0.9 .341
Spontaneous beat after
declamping (%)
69 89 .087
Inotropes at weaning from
CPB (%)
19 0 .025
Inotropic support duration
(hours)
100 13 115 11 .373
Ventilatory support duration
(hours)
99 23 86 15 .641
ICU stay (days) 9.5 1.5 7.4 0.9 .226
Mortality (%) 15.4 3.9 .175
Data are shown as the mean  standard error of the mean or the
percentage of the patients in each group. Myocardial temperature in the
group T was the temperature just prior to the start of TWBCP infusion.
CPB, Cardiopulmonary bypass; AoX, aortic crossclamp; ICU, intensive care
unit.
Figure 7. Effects of TWBCP in patients with cyanosis. Lactate
extraction rate during initial 60 minutes of reperfusion after aortic
crossclamp release. All results are shown as mean  standard
error of mean for each group. Significant differences: *P < .05
versus control.
Figure 8. Effects of TWBCP in patients with cyanosis. Serum
concentration of cardiac troponin T 0, 1, 3, 6, and 18 hours after
aortic crossclamp release. All results are shown as mean 
standard error of mean for each group.
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its low molecular weight and cytosolic location.9 Our data
showed that h-FABP was significantly decreased at 2 and 3
hours after reperfusion in group T compared with group C,
indicating that less myocardial injury, not always necrosis,
occurred with TWBCP.
In physiological conditions, fatty acids, lactate, and glu-
cose are taken from blood into myocardial cells and used as
myocardial metabolic substrates. Of these, fatty acids rep-
resent the principal metabolic substrate in myocardial cells;
however, during ischemia, fatty acid oxidation is inhibited
and glycolytic adenosine triphosphate (ATP) production
predominates, resulting in lactate production and release
into the extracellular space.14 Namely, lactate release from
the ischemic myocytes is considered as an index of anaer-
obiosis. Myocardial lactate extraction rate stayed negative
in group C, indicating that the amount of lactate production
through the anaerobic glycolysis was greater than the
amount of lactate used for aerobic energy production. These
data indicate continued anaerobic energy metabolism and
prolonged impairment of normal aerobic metabolism during
the first 60 minutes of reperfusion in hearts receiving cold
blood cardioplegia and topical cardiac cooling only. In
contrast, our data show that myocardial lactate extraction
rate was increased at all time points in group T compared
with group C, and the crossover point of lactate extraction
rate from negative to positive was observed at 30 minutes of
reperfusion. This indicates that lactate consumption and
production were equilibrated at 30 minutes of reperfusion in
hearts receiving TWBCP, and thereafter lactate extraction
became positive. This crossover point shows that myocar-
dial tissue starts to use lactate as a substrate via oxidative
phosphorylation.14 These data demonstrate that TWBCP
accelerates the recovery of aerobic energy metabolism.
The mechanisms of TWBCP by which TWBCP affords
cardioprotection in adult patients have been shown to in-
clude the following: (1) warm blood accelerates recovery of
temperature-dependent enzymatic and metabolic function
and provides oxygen; (2) high potassium prolongs electro-
mechanical arrest to decrease energy demands; (3) low
calcium prevents intracellular calcium overload, which is
believed to be the major cause of ventricular contracture and
reperfusion injury; (4) alkalotic solution counteracts tissue
acidosis and optimizes enzymatic and metabolic function;
and, (5) high osmolarity counteracts tissue edema.2,6,15-17
We have used the same solution as cold blood cardioplegia
for TWBCP by just warming cold blood cardioplegia to
35°C. The composition of our TWBCP solution meets the
requirement of above-mentioned proposed mechanisms. At
18 mmol/L, the level of K was high enough to keep the
heart from recurring electromechanical activities, and none
of the hearts showed any electromechanical activities during
TWBCP infusion.
Because TWBCP is given at the end of global ischemia
just before reperfusion, TWBCP is expected to reduce
reperfusion injury after ischemia. At the onset of reperfu-
sion after the aortic crossclamp release, we routinely re-
duced coronary artery perfusion pressure to less than 30 mm
Hg by partially declamping the aorta for 3 minutes and
Ca2 concentration to less than 0.7 mmol/L with citrate-
phosphate-dextrose to prevent intracellular calcium accu-
mulation in all patients. Therefore, the major differences in
the composition of reperfused solution between the two
groups were in potassium concentration, pH, and osmolar-
ity. TWBCP included significantly higher concentration of
potassium, higher pH, and higher osmolarity compared with
circulating blood at the onset of reperfusion. Thus, we
speculate that cardioprotection with TWBCP was achieved
with prolonging electromechanical arrest and counteracting
myocardial tissue acidosis and edema.
Our results show that TWBCP improved lactate metab-
olism and reduced myocardial injury and necrosis, and with
such mechanisms TWBCP had favorable effects on clinical
outcome parameters. The improved lactate metabolism in-
dicates improved aerobic production of high-energy phos-
phates that would presumably occur through prolonging the
electromechanical arrest by high potassium, which reduces
energy demands, and through counteracting tissue acidosis.
Intracellular acidosis activates Na-H exchanger leading
to increased Na concentration in the cytosol, which would
further activate Na-K pump to decrease intracellular Na
concentration with the consumption of ATP and Na-Ca2
exchanger, leading to increased intracellular Ca2 concen-
tration.18 To reduce intracellular Ca2 concentration, ATP
would be consumed further to activate Ca2 pumps on the
sarcolemma and sarcoplasmic reticulum. Thus, these two
constituents of TWBCP, high potassium and high pH,
would contribute to the reduced myocardial injury and
necrosis by preservation and resynthesis of high-energy
phosphates.
The mean age of the patients in this study was 5.6  0.4
years, and only 3 neonates were included. Therefore, we
could not draw any conclusions in terms of the effect of
TWBCP on neonatal hearts, which obviously needs to be
elucidated. However, we examined the patients whose ages
were equal to or less than 2 years (Table 5 and Figures 5 and
6). Interestingly, our data showed that the crossover point of
lactate extraction rate in group T was observed at 20 min-
utes of reperfusion, which was 10 minutes earlier compared
with the entire study group, indicating that the recovery of
lactate extraction might be quicker with TWBCP in the
younger hearts compared with the older hearts. Cardiac
troponin T was decreased with TWBCP at any time point
and the difference between the groups seemed more prom-
inent (Figure 6), although no statistical significance was
observed as a result of the small number. These data suggest
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that immature hearts might be provided better myocardial
protection by TWBCP compared with mature hearts.
We also examined the patients with cyanosis separately
(Table 6 and Figures 7 and 8). Our data showed that no
significant differences in lactate extraction were observed
between the groups after up to 45 minutes, and the crossover
point in group T was observed between 45 and 60 minutes
of reperfusion, indicating that the effect of TWBCP on
lactate metabolism was less evident and the recovery of
lactate extraction was slower in patients with cyanosis com-
pared with the entire study group. The underlying mecha-
nisms of delayed recovery of lactate extraction could be
impaired aerobic energy metabolism or reduced lactate
washout19 from the hypertrophied myocardium in patients
with cyanosis. No significant differences in cardiac troponin
T were observed between the groups at any time point.
These data suggest that cyanotic hearts might be less ben-
efited by TWBCP compared with acyanotic hearts. How-
ever, the effects and the mechanisms of TWBCP on cya-
notic hearts remain to be elucidated.
In conclusion, our data indicate that TWBCP has cardio-
protective effects in children and adolescents, as it does in
adults, and TWBCP affords an additional myocardial pro-
tection by improvement in aerobic energy metabolism and
reduction of myocardial injury or necrosis, suggesting that
TWBCP would allow for enhanced myocardial protection in
pediatric heart surgery and should be used routinely as in
adult heart surgery.
We express our appreciation to Sachiko Kido, MD, for assis-
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her administrative assistance. We also wish to extend our appre-
ciation to the physicians in the division of cardiac surgery of Kobe
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Discussion
Dr B. Allen (Oak Lawn, Ill). Cardioplegic application in con-
genital heart surgery has made tremendous gains over the past 10
years; however, recovery and outcome statistics continue to point
out the need for improvements in this increasingly younger patient
population. In general, advancements in myocardial protection
strategies have benefited from the adult cardiac experience. Nev-
ertheless, in view of the structural, functional, and metabolic
differences, extrapolation of adult cardioprotective strategies to the
pediatric population may be fundamentally imprudent and poten-
tially harmful.
A terminal warm cardioplegic reperfusate is a routine part of
most adult heart procedures. In contrast, a warm blood cardiople-
gic reperfusate is rarely used in infants, perhaps because of the
belief that the infant heart is more tolerant to ischemia. Dr Toyoda
and his colleagues are to be commended for investigating this
question with a randomized clinical trial. These studies are often
difficult because, unlike the experimental laboratory where vari-
ables can be precisely controlled and measured, the preoperative
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